Vicarious Surgical, a next-generation surgical robotics company, reported fourth quarter 2025 results with total operating expenses of $9.3 million, down 38% year-over-year. Full year operating expenses decreased 25% to $50.0 million. The company posted a GAAP net loss of $10.5 million for Q4 2025, or $1.57 per share, compared to $13.9 million, or $2.36 per share, in Q4 2024. Full year GAAP net loss was $50.2 million, or $8.19 per share, down from $63.2 million in 2024. Vicarious Surgical ended 2025 with $9.8 million in cash and investments. The company's full year cash burn of $45.1 million came in below its initial guidance of approximately $50 million. For 2026, the company expects cash burn of approximately $19 million.

Surgerii Robotics raises $100M to fund global expansion. The China-based surgical robot manufacturer is gearing up for growth after receiving Europe's CE mark last year for its single port endoscopic system. Dive brief: * Beijing-based Surgerii Robotics said it closed a $100 million Series D financing round led by Loyal Valley Capital, a private equity group based in Shanghai. * The funds will be used to accelerate global commercialization and clinical adoption of the company's SHURUI single port endoscopic surgical robot and development of next-generation products, Surgerii said in a LinkedIn post last week. * The robot is intended for use in urologic, gynecologic, general and thoracoscopic procedures in both adult and pediatric patients. The financing round follows the company's CE mark in August for the system. Dive insight: Surgerii is quickly scaling up adoption of its robotic surgery platform. The company said in another recent LinkedIn post that the robot launched commercially in late 2024 in China, where more than 3,000 human surgeries have been performed with the system. In August, the company said it had collaborated with more than 70 hospitals in China and nearly 10 in Europe. Surgerii also established a European training center last year in a partnership with IRCAD, a surgical education and research institute based in France. Medtronic, which received Food and Drug Administration clearance for its Hugo surgical robot in December, teamed last year with IRCAD's North American arm. In a robotic surgery market where competition is rapidly intensifying, Surgerii sees its system as offering capabilities for multi-directional maneuvering of instruments through a single incision to reduce surgical trauma and speed patient recovery. The robot competes internationally with Intuitive Surgical's da Vinci single port system, which gained new indications in the U.S. in December for inguinal hernia repair, gallbladder removal and appendectomy procedures. Other robot makers with single port systems include Virtual Incision, which won FDA de novo authorization in 2024 for its MIRA system in colectomy procedures and is now working on a next-generation version, and Vicarious Surgical, which is developing a single port system for abdominal procedures. Also participating in Surgerii's funding round were Shanghai Healthcare Capital, V Star Capital, DNV Capital and Hefei Industrial Investment.